Re­gen­eron plans for quick re­de­ci­sion on CRL for high­er dose of Eylea

Re­gen­eron saw its stock price rise by more than 6% on Thurs­day af­ter an­nounc­ing a faster than ex­pect­ed de­ci­sion on its soon-to-be re­sub­mit­ted ap­pli­ca­tion for a high­er dosage ver­sion of its block­buster Eylea (afliber­cept).

Lat­er this quar­ter Re­gen­eron said it would hear back from FDA with a re­sponse to de­fi­cien­cies in man­u­fac­tur­ing that were un­cov­ered at its con­tract man­u­fac­tur­er Catal­ent.

An an­a­lyst re­port from Leerink Part­ners on Thurs­day not­ed that the an­nounced tim­ing is “faster than many ex­pect­ed” as a six month res­bu­mis­sion time­line was spec­u­lat­ed when the CRL was hand­ed down in June. How­ev­er, Leerink not­ed that if the FDA find the in­for­ma­tion from Catal­ent isn’t enough to solve the is­sues, the FDA may re­quire more da­ta, qual­i­ty stud­ies, rein­spec­tions or oth­er in­for­ma­tion, drag­ging out the time­line fur­ther.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER